Using all we have or wait - modern management of metastatic RCC

Poster Session 01

Location: Green Area, Room 2 (Level 0)

Chairs: A. Bamias, Athens (GR)
J. Bedke, Tübingen (DE)
M. Eto, Fukuoka (JP)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

Surgical safety of immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib. Data from the EORTC randomized trial 30073 SURTIME


1 The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, Netherlands, The Netherlands
2 Radboud University, Dept. of Urology, Nijmegen, Netherlands, The Netherlands
3 Princess Margaret Hospital, Dept. of Urology, Toronto, Canada
4 Singleton Hospital, Dept. of Oncology, Swansea, United Kingdom
5 Institut Bordelet, Dept. of Urology, Brussels, Belgium
6 AMC, Dept. of Urology, Amsterdam, Netherlands, The Netherlands
7 Queen Elizabeth Hospital, Dept. of Oncology, Halifax, Canada
8 St Antonius Hospital, Dept. of Urology, Nieuwegein, Netherlands, The Netherlands
9 Maastricht University Hospital, Dept. of Oncology, Maastricht, Netherlands, The Netherlands
10 CHUM St Luc, Dept. of Urology, Montréal, Canada
11 St Bartholomews Hospital, Dept. of Oncology, London, United Kingdom
12 Groningen University Hospital, Dept. of Urology, Groningen, Netherlands, The Netherlands
13 UZ Gent, Dept. of Oncology, Ghent, Belgium
14 University Hospital St Luc, Dept. of Urology, Brussels, Belgium
15 EORTC, Dept. of Statistics, Brussels, Belgium
16 The Netherlands Cancer Institute, Dept. of Oncology, Amsterdam, Netherlands, The Netherlands

*1

High competing risks minimize real-world utility of adjuvant targeted therapy in renal cell carcinoma: A population-based analysis

By: Chandrasekar T., Klaassen Z., Goldberg H., Sayyid R., Kulkarni G., Fleschner N.

1 University Health Network, University of Toronto, Dept. of Surgical Oncology, Division of Urologic Oncology, Toronto, Canada
2 Augusta University, Dept. of Urology, Augusta, United States of America

Systematic review and meta-analysis of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma
Natural history of collecting duct carcinoma: A unique multi-institutional study with a centrally-reviewed pathology

By: Ouzaid I. ¹, Comperat E. ², Rouprêt M. ³, Rioux-Leclerc N. ⁴, Descotes J. ⁵, Verkarre V. ⁶, Bernhard J-C. ⁷, Barthélémy P. ⁸, Malouf G. ⁹

¹Bichat Hospital, Dept. of Urology, Paris, France, ²Tenon Hospital, Dept. of Pathology, Paris, France, ³CHU Pitié-Salpêtrière, Dept. of Urology, Paris, France, ⁴CHU Rennes, Dept. of Pathology, Rennes, France, ⁵CHU Grenoble, Dept. of Urology, Grenoble, France, ⁶CHU Georges Pompidou, Dept. of Pathology, Paris, France, ⁷CHU Bordeaux, Dept. of Urology, Bordeaux, France, ⁸CHU Strasbourg, Dept. of Medical Oncology, Strasbourg, France, ⁹CHU Pitié-Salpêtrière, Dept. of Medical Oncology, Paris, France

Validation of the IMDC prognostic model in metastatic renal cancer at diagnosis and investigation of it’s role in the prediction of outcome from cytoreductive nephrectomy

By: Hendry J. ¹, Beh I. ², Clement K. ¹, O’Connor K. ², Riddick A. ², Stewart G. ², Aboumarzouk O. ¹, McNeill A. ², Leung S. ², Oades G. ¹, Laird A. ²

¹Queen Elizabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom, ²NHS Lothian, Dept. of Urology, Edinburgh, United Kingdom

PD-L1 expression is associated with tumor progression and poor prognosis in Xp11.2 translocation renal cell carcinoma

Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

Tumor-infiltrating neutrophils predict therapeutic benefit of tyrosine kinase inhibitors in metastatic renal cell carcinoma

By: Wang J. ¹, Liu L. ¹, Ou C. ², Xu J. ², Guo J. ¹

¹Zhongshan Hospital of Fudan University, Dept. of Urology, Shanghai, China, ²Fudan University, Shanghai Medical College, Dept. of Biochemistry, Shanghai, China

The effect of fourth-line systemic therapy in metastatic renal cell carcinoma

Tumoral CD8+ T cells correlate with favorable outcome in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors

By: Wang J.1, Liu L.1, Xi W.1, Xu J.2, Guo J.1
1Zhongshan Hospital, Fudan University, Dept. of Urology, Shanghai, China, 2Fudan University, Shanghai Medical College, Dept. of Biochemistry, Shanghai, China

Sunitinib or sorafenib as neoadjuvant therapy may not improve the survival outcomes of renal cell carcinoma with tumor thrombus

By: Huang J., Cai W., Dong B., Li M., Kong W., Zhang J., Chen Y., Xue W., Huang Y.
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China

Statins and prognosis of renal cell cancer: A retrospective Finnish cohort study

By: Eskelinen T.1, Tammela T.2, Kotsar A.3, Murtola T.2
1Tampere University Hospital, School Of Medicine, Tampere, Finland, 2Tampere University Hospital, Dept. of Urology, Tampere, Finland, 3Tarto University, Dept. of Urology, Tarto, Estonia

Summary
J. Bedke, Tübingen (DE)